Navigation Links
Roche Extends Tender Offer for Ventana
Date:10/29/2007

BASEL, Switzerland, Oct. 29 /PRNewswire/ -- Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (Nasdaq: VMSI) to 5:00 p.m., New York City time on Thursday, January 17, 2008. The tender offer was previously scheduled to expire at 5:00 p.m., New York City time, on November 1, 2007. All other terms and conditions of the tender offer remain unchanged.

On June 27, 2007, Roche commenced a tender offer to acquire all of the outstanding common shares of Ventana for $75.00 per share in cash. This price represents a 44% premium to Ventana's close of $51.95 on June 22, 2007 (the last trading day prior to the announcement of Roche's offer) and a 55% premium to its three-month average as of the same date of $48.30. As of the close of business on October 29, 2007, approximately 63,711 shares have been tendered pursuant to the offer.

Greenhill & Co. and Citi are acting as financial advisors to Roche and Davis Polk & Wardwell is acting as legal counsel.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Roche offers HIV drug expertise to poor nations
2. Roche Commits More Antiviral Pills To Asia For Bird Flu
3. FDA Imposes New Restrictions On Roches Accutane
4. Roche confirms Tamiflu production talks in US
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Roche Rolls Out Lung Cancer Drug In India
7. New Lung Cancer Drug Launched By Roche Pharmaceutical
8. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
9. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
10. NICE Gives the Final ‘NO’ to Roche’s Tarcva
11. Roche Announces Major Recall of HIV Drug
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Confusion Over Homeopathic Medicines in Alexa Ray Joel's Hospitalization Clarified by the American Association of Homeopathic Pharmacists (AAHP) 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 1DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 3DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 4DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 5DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 6Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 1Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 2Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 1YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 2YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 4